A look at incidence rates, survival rates, and more.
It’s widely known that deaths from cancer are falling due to new treatments and more accurate detection.To help illustrate how cancer care and detection have changed, we looked at data from the National Cancer Institute to find out how rates of one cancer type-Non-Hodgkin’s Lymphoma-have changed from 1975 to 2016 (the first year of tracked data to the most recent), also looking at the decades in between.What the data show are that cancer incidence has increased over the decades (though it has fallen in recent years), death rates have fallen dramatically since their peak at the beginning of the 21st century.
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.